<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02350842</url>
  </required_header>
  <id_info>
    <org_study_id>ICSY02</org_study_id>
    <nct_id>NCT02350842</nct_id>
  </id_info>
  <brief_title>Triple-site Biventricular Stimulation in the Optimization of CRT</brief_title>
  <acronym>TRIUMPH-CRT</acronym>
  <official_title>Triple-site Biventricular Stimulation in the Optimization of Cardiac Resynchronization Therapy (CRT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LivaNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LivaNova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac resynchronization is a recommended therapy for patients with advanced heart failure,
      under optimized medical treatment with reduced left ventricular ejection fraction and
      prolonged QRS, nevertheless, still 30% of the population do not respond to standard
      biventricular implantation.

      Non-response can be explained by a combination of factors including sub-optimal patient
      selection, placement of the pacing lead over a zone of slow conduction, insufficient
      correction of mechanical dyssynchrony including sub-optimal lead implantation. Few data
      distinguish true non-responders from patients in which effective resynchronization was not
      delivered through standard biventricular implantation.

      Triple-site cardiac resynchronization pacing (stimulation at three ventricular sites) has
      been proposed to improve synchrony and thus the response rate in (Cardiac Resynchronisation
      Therapy) CRT recipients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The frequent failure of CRT in non-Left Bundle Branch Block (non-LBBB) patients is suspected
      to be due to more complex and heterogeneous forms of electrical/mechanical dyssynchronies
      needing more complex and individualized pacing configurations to be corrected.

      Acute studies during implant show that standard biventricular pacing provides optimal
      mechanical improvement only in a minority of patients. In a peri-operative echo-guided leads
      placement procedure most of non-improved patients could be successfully mechanically
      resynchronized. A significant number of patients required optimized placement of right
      ventricular (RV) lead and/or triple-site configurations.

      These studies led to the hypothesis that more complex and individualized pacing
      configurations (Triple-site biventricular) might increase the number of responders to CRT.

      To assess this hypothesis, this study will be conducted in Class II-ambulatory IV patients
      indicated for CRT with wide QRS (≥ 140 ms) and non-LBBB. Patients will be randomized in a 1:1
      configuration:

        -  Standard biventricular pacing (1 right ventricular/1 left ventricular (1RV/1LV)) through
           classical implantation procedure without peri-operative optimization

        -  Triple-site biventricular pacing with individual optimization of the placement of the
           third lead by peri-operative echo guidance.

      The objective of the optimization process is to improve LV efficiency and to decrease the
      left pre-ejection interval (LPEI, defined as the time interval between the onset of QRS and
      the onset of LV ejection) as much as possible compared with a standard biventricular
      configuration by moving a second right ventricular lead at different locations.

      LPEI is simple to measure, with good inter- and intra-observer reproducibility and its
      utility has previously been strongly suggested.

      Reduction in LPEI results in decreased duration of ventricular systole and is associated with
      improved LV filling and reduced interventricular delay.

      The primary objective of this study is to demonstrate that individually optimized,
      triple-site biventricular pacing is superior to standard biventricular pacing in reverse
      ventricular modeling as demonstrated by Echo Left Ventricle End-Systolic Volume (LVESV) at 1
      year in patients with non-LBBB morphology without increasing the risk of serious procedure
      and/or device related adverse events at 30 days.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate reverse ventricular remodeling response through change in Left Ventricle End-Systolic Volume comparing both groups in a superiority context</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence of serious procedure and/or device related events</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate reverse ventricular remodeling response based on additional echocardiographic measures</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Change in left ventricular (LV) volumes (end-systolic and end-diastolic volumes) and LV ejection fraction will be evaluated as part of reverse remodeling response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's clinical status considering New York Heart Association (NYHA) functional class improvement</measure>
    <time_frame>1, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate patient's clinical status considering death from any cause, heart-failure-related hospitalizations and the incidence of serious device related events</measure>
    <time_frame>1, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Triple-site biventricular pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Triple-site biventricular pacing with individual optimization of the placement of the third lead by peri-operative echo guidance. Devices used will be the Sorin, locally approved and commercially available Paradym SonR Tri-V CRT-D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard biventricular pacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard biventricular pacing (1RV/1LV) through classical implantation procedure without peri-operative optimization. Devices used will be locally approved and commercially available Sorin implantable cardioverter defibrillators.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>triple-site biventricular pacing with peri-operative echo guidance</intervention_name>
    <description>placement of the third lead by peri-operative echo guidance.</description>
    <arm_group_label>Triple-site biventricular pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>standard biventricular pacing</intervention_name>
    <description>standard biventricular pacing without optimization by echo guidance</description>
    <arm_group_label>Standard biventricular pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years

          -  Stable heart failure with New York Heart Association (NYHA) functional class II, III
             or ambulatory IV

          -  Stable optimized medical regimen according to medical guidelines (No change in heart
             failure medication for at least 1 month prior to enrollment)

          -  Left ventricular ejection fraction (LVEF) ≤ 35%

          -  Intrinsic QRS duration ≥ 140 msec

          -  Non-typical left bundle branch block (LBBB) morphology on 12-lead surface ECG

          -  Signed and dated informed consent

        Exclusion Criteria:

          -  Typical LBBB according to Strauss criteria

          -  Unstable heart failure

          -  Permanent or long-lasting persistent Atrial Fibrillation

          -  Unstable angina, acute Myocardial Infarction (MI), Coronary Artery Bypass-Grafting
             (CABG), or Percutaneous Transluminal Coronary Angioplasty (PTCA) within 90 days prior
             to enrollment (intervention)

          -  Conventional pacemaker indication

          -  Previous implant with a pacemaker or an Implantable Cardioverter-Defibrillator (ICD)

          -  Renal Failure (Glomerular filtration rate (GFR) &lt; 30 ml/min/1.73m2)

          -  Pregnant women

          -  Already included in another clinical study that could confound the results of this
             study

          -  Life expectancy &lt; 12 months

          -  Mechanical heart valve or indication for valve repair or replacement

          -  Recent Cerebro-Vascular Accident (CVA) or Transient Ischemic Attack (TIA) (within the
             previous 3 months)

          -  Heart transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Claude Daubert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Pontchaillou-CHU Rennes, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU Hopital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Rhone Durance</name>
      <address>
        <city>Avignon</city>
        <zip>84082</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Minjoz Besançon</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe hospitalier Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <zip>75614</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Poitiers</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse, Hopital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>D-24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humanitas Cliniche Gavazzeni spa</name>
      <address>
        <city>Bergamo</city>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Zwolle</name>
      <address>
        <city>Zwolle</city>
        <zip>8025AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHCL - Hospital Santa Marta</name>
      <address>
        <city>Lisbon</city>
        <zip>1169-024</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>8025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2015</study_first_submitted>
  <study_first_submitted_qc>January 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2015</study_first_posted>
  <last_update_submitted>September 12, 2017</last_update_submitted>
  <last_update_submitted_qc>September 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>non-Left Bundle Branch Block morphology</keyword>
  <keyword>Triple-site biventricular pacing</keyword>
  <keyword>cardiac resynchronization therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

